We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+33.14%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$7.1B
AUM Growth
+$1.15B
Cap. Flow
-$108M
Cap. Flow %
-1.52%
Top 10 Hldgs %
31.14%
Holding
166
New
24
Increased
29
Reduced
28
Closed
31

Top Buys

Rank Stock Value
1
BNR
Burning Rock Biotech
BNR
+$130M
2
RPTX
Repare Therapeutics
RPTX
+$110M
3
ORIC icon
Oric Pharmaceuticals
ORIC
+$93.3M
4
BIIB icon
Biogen
BIIB
+$70.8M
5
TBPH icon
Theravance Biopharma
TBPH
+$60.2M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$237M
2
PFE icon
Pfizer
PFE
+$98.3M
3
GILD icon
Gilead Sciences
GILD
+$98M
4
ALEC icon
Alector
ALEC
+$64.9M
5
HCA icon
HCA Healthcare
HCA
+$63.8M

Sector Composition

Rank Sector Weight
1 Healthcare 97.96%
2 Financials 1.61%
3 Miscellaneous 0.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRPT icon
26
Sarepta Therapeutics
SRPT
$2.21B
$89.7M 1.26%
559,649
-342,800
-38% -$46.6M
CNC icon
27
Centene
CNC
$34.3B
$84.9M 1.2%
1,335,700
– –
CI icon
28
Cigna
CI
$74.2B
$82.5M 1.16%
439,700
– –
ETNB
29
DELISTED
89bio
ETNB
$79.8M 1.12%
4,004,442
– –
ELVN icon
30
Enliven Therapeutics
ELVN
$3.99B
$75.2M 1.06%
679,976
– –
ADVM
31
DELISTED
Adverum Biotechnologies
ADVM
$68.7M 0.97%
329,074
-15,990
-5% -$2.83M
DCPH
32
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$67.2M 0.95%
1,125,700
-31,900
-3% -$1.71M
ISRG icon
33
Intuitive Surgical
ISRG
$134B
$64.3M 0.9%
338,400
-168,900
-33% -$30.3M
KROS icon
34
Keros Therapeutics
KROS
$222M
$63M 0.89%
+1,679,417
New +$51.7M
EHTH icon
35
eHealth
EHTH
$29.6M
$62.7M 0.88%
638,558
– –
NXTC icon
36
NextCure
NXTC
$30.4M
$58.1M 0.82%
225,918
– –
EXEL icon
37
Exelixis
EXEL
$13.9B
$57.1M 0.8%
2,404,100
-776,000
-24% -$18M
KALA icon
38
KALA BIO
KALA
$10.5M
$56.8M 0.8%
2,163
– –
FUSN
39
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$56.3M 0.79%
+3,224,770
New +$56.2M
ATRC icon
40
AtriCure
ATRC
$2.84B
$55.2M 0.78%
1,228,189
+300,000
+32% +$13.1M
ATNX
41
DELISTED
Athenex, Inc. Common Stock
ATNX
$55.2M 0.78%
200,467
– –
LOGC
42
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
$54.7M 0.77%
6,466,783
– –
TBPH icon
43
Theravance Biopharma
TBPH
$883M
$53.6M 0.75%
2,554,470
+2,342,925
+1,108% +$60.2M
BLU
44
DELISTED
BELLUS Health Inc.
BLU
$53M 0.75%
5,137,216
-1,888,616
-27% -$19.1M
CRSP icon
45
CRISPR Therapeutics
CRSP
$5.12B
$51.3M 0.72%
697,524
+146,324
+27% +$8.56M
CRNX
46
DELISTED
Crinetics Pharmaceuticals
CRNX
$48.2M 0.68%
2,753,567
+714,285
+35% +$12.2M
GKOS icon
47
Glaukos
GKOS
$10.1B
$46.5M 0.66%
1,211,000
-336,646
-22% -$12.5M
MGTX icon
48
MeiraGTx Holdings
MGTX
$1.23B
$46.5M 0.65%
3,713,820
+131,500
+4% +$1.83M
ABBV icon
49
AbbVie
ABBV
$454B
$45.6M 0.64%
464,000
+235,000
+103% +$20.7M
MRSN
50
DELISTED
Mersana Therapeutics
MRSN
$44.7M 0.63%
76,400
+22,531
+42% +$7.69M
1
2
3 4 5

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q2 2020 Portfolio in Review

As of Q2 2020, OrbiMed held 166 positions worth $7.1B, up 19% from $5.95B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

OrbiMed's Q2 2020 filing shows 24 new, 29 increased, 28 reduced and 31 closed positions. Its largest new stake was Burning Rock Biotech: 474,607 shares worth $128M. The largest sale was Ascendis Pharma A/S, an estimated $237M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Financials and Miscellaneous.

  • OrbiMed's largest Q2 2020 buy was Burning Rock Biotech: 474,607 shares worth $128M.
  • OrbiMed added most to Biogen in Q2 2020, an estimated $70.8M increase.
  • OrbiMed's biggest Q2 2020 reduction was Ascendis Pharma A/S, cutting an estimated $237M.
  • OrbiMed fully exited Pfizer in Q2 2020, selling an estimated $98.3M.
  • OrbiMed's ten largest holdings make up 31% of its $7.1B portfolio in Q2 2020.
  • OrbiMed opened 24 new positions and closed 31 in Q2 2020.
  • OrbiMed's portfolio value rose 19% quarter-over-quarter to $7.1B.

Based on OrbiMed's 13F filing for Q2 2020, filed 14 Aug 2020.